berberine has been researched along with Insulin Resistance in 119 studies
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this double-blind, placebo-controlled trial, adults living with HIV under virological suppression and metabolic syndrome received either berberine 500 mg TID or placebo for 20 weeks." | 9.69 | Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection. ( Alvarez-Zavala, M; Andrade-Villanueva, JF; González-Hernández, LA; Martínez-Ayala, P; Méndez-Clemente, AS; Navarro-Lara, SA; Ruiz-Herrera, VV; Sánchez-Reyes, K; Toscano-Piña, M; Valle-Rodríguez, A, 2023) |
| " The aim of this one-group pretest-post-test explanatory study was to evaluate, in normal-overweight PCOS women with normal menses, the effectiveness of berberine on: Insulin resistance (IR) by Homeostasis Model Assessment (HOMA); Inflammation by C-Reactive Protein (CRP), Tumor Necrosis Factor α (TNF-α); Lipid metabolism; Sex hormone profile and symptoms correlated to hyperandrogenism, such as acne, by Global Acne Grading System (GAGS) and Cardiff Acne Disability Index (CADI); Body composition by DXA." | 9.41 | Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study. ( Allegrini, P; Bernardinelli, L; Fazia, T; Gasparri, C; Giacosa, A; Perna, S; Peroni, G; Petrangolini, G; Riva, A; Rondanelli, M, 2021) |
| " This randomized controlled trial aims to evaluate the efficacy and safety of berberine in the treatment of patients with polycystic ovary syndrome." | 9.22 | The effect of berberine on insulin resistance in women with polycystic ovary syndrome: detailed statistical analysis plan (SAP) for a multicenter randomized controlled trial. ( Chai, QY; Liu, JP; Ma, HL; Sun, J; Wu, XK; Zhang, K; Zhang, Y; Zhang, YJ, 2016) |
| "The aim of this study was to evaluate the effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion." | 9.17 | Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ( Espinel-Bermúdez, MC; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA, 2013) |
| "We postulate that women with PCOS will have improved insulin resistance following berberine administration." | 9.17 | Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. ( Hou, L; Kuang, H; Li, Y; Ma, H; Ng, EH; Wu, X; Zhang, Y, 2013) |
| "The objective of the study was to evaluate the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia." | 9.13 | Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. ( Hong, J; Huo, L; Li, X; Liu, W; Ning, G; Ren, G; Wang, M; Wu, P; Yang, J; Zhang, Y; Zhu, N; Zou, D, 2008) |
| "Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc." | 9.12 | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. ( Cai, B; Chen, Q; Wang, S; Xu, Z, 2021) |
| "This study provides a critical overview of experimental studies in vitro, in humans, and in animals that evaluated the efficacy of Berberine and its effect on management of obesity and the related metabolic consequences." | 9.05 | The effect of Berberine on weight loss in order to prevent obesity: A systematic review. ( Al-Thawadi, S; Alalwan, TA; Gasparri, C; Ilyas, Z; Infantino, V; Perna, S; Peroni, G; Petrangolini, G; Riva, A; Rondanelli, M, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 8.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| "To investigate whether astragalus polysaccharides (APS) combined with berberine (BBR) can reduce high-fat diet (HFD)-induced obesity in mice." | 8.31 | Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice. ( Feng, WW; Gao, H; Liu, J; Tang, YP; Wang, WX; Yan, D; Yue, SJ; Zhang, L, 2023) |
| " It is widely reported that berberine (BBR) has an anti-inflammatory effect and can reduce glucose and lipid accumulation, whereas ginsenoside Rb1 (Rb1) has been shown to have a significant inhibitory effect on insulin resistance and lipid peroxidation." | 8.02 | Synergetic protective effect of berberine and ginsenoside Rb1 against tumor necrosis factor alpha-induced inflammation in adipocytes. ( Cai, Z; Chen, Y, 2021) |
| "Berberine has been found to exhibit an array of pharmacological activities relating to the lowering of blood glucose and the treatment of polycystic ovarian syndrome (PCOS)." | 7.96 | Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. ( Fang, J; Li, F; Liu, X; Liu, Z; Shan, Y; Wang, Y; Zhang, N; Zhao, H; Zhuang, L, 2020) |
| "To study the role of selected serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome (PCOS)." | 7.96 | The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome. ( Ai, W; Duan, Y; Kuang, H; Li, D; Li, M; Li, W; Liu, S; Liu, X; Shao, M; Wang, Y; Xu, Y, 2020) |
| "To elucidate the protective effect of berberine on olanzapine induced-metabolic syndrome." | 7.91 | Berberine attenuates olanzapine induced-metabolic syndrome. ( Al-Gareeb, AI; Al-Kuraishy, HM; Al-Naimi, MS; Rasheed, HA, 2019) |
| "Berberine, a natural compound extracted from several Chinese herbs including Coptis chinensis, has been shown to have anti-obesity effects and prevents insulin resistance in high-fat diet (HFD)-fed obese rats by modulating the gut microbiota; however, the molecular mechanisms underlying these activities remain unknown." | 7.88 | Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. ( Hou, L; Li, S; Liu, D; Liu, Y; Tian, H; Zhang, Y; Zhao, T, 2018) |
| "The results showed that administration of berberine for 6 months significantly improved cognitive deficits and insulin resistance in naturally aging rats (p<0." | 7.88 | Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats. ( Chen, L; Guan, F; Guan, Y; Li, J; Lv, X; Teng, F; Xu, J; Yu, Y; Zhang, M; Zhao, Y, 2018) |
| " In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1β (IL-1β) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue." | 7.85 | Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement. ( Feng, L; Liu, H; Ma, Y; Shen, Y; Sun, Y; Wu, X; Xu, F; Xu, G; Xu, Q; Zhang, X; Zhou, H, 2017) |
| "Berberine improves diabetic vascular insulin sensitivity and mesenteric vasodilatation by up-regulating insulin receptor-mediated signalling in diabetic rats." | 7.83 | Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats. ( Dong, L; Dong, MQ; Gao, F; Geng, FH; Li, GH; Zhang, P; Zhang, X; Zhang, Y; Zhao, ZJ, 2016) |
| "To explore the possible mechanism of berberine improve insulin resistance in skeletal muscle of obese rats." | 7.81 | [Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance]. ( Bai, XH; Chen, J; Mu, DZ; Yao, YJ; Zhang, DS, 2015) |
| " Berberine (BBR) is a plant alkaloid which promotes hypoglycemia via increasing insulin sensitivity in peripheral tissues." | 7.79 | Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase. ( Chang, W; Chen, L; Du, H; Hatch, GM; Li, J; Meng, Z; Wei, S; Zhang, M, 2013) |
| "Berberine exerts insulin resistance-improving effects, the underlying mechanism of which is not well understood." | 7.78 | A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats. ( Gao, FY; Gu, JJ; Zhao, TY, 2012) |
| "Theca cells with dexamethasone-induced insulin resistance showed defective glucose uptake and excessive testosterone production, both of which were effectively antagonized by berberine." | 7.77 | Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. ( Baillargeon, JP; Han, F; Hou, L; Kuang, H; Li, W; Wang, Y; Wu, X; Zhao, L, 2011) |
| "Berberine, a major isoquinoline alkaloid present in Chinese herb Rhizoma coptidis, is a potent inhibitor of inflammation and has anti-diabetic activity." | 7.77 | Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. ( Huang, F; Li, L; Liu, B; Liu, K; Lou, T; Xi, Z; Zhang, Z, 2011) |
| "This study was performed to investigate the molecular mechanism and the therapeutic effect of berberine on nonalcoholic fatty liver disease (NAFLD)." | 7.77 | Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. ( Hua, YQ; Ji, G; Liu, T; Xing, LJ; Zhang, L; Zheng, PY, 2011) |
| "To explore the effects of berberine on the pancreatic 13 cell apoptosis in rats with insulin resistance (IR)." | 7.77 | [Effects of berberine on the pancreatic beta cell apoptosis in rats with insulin resistance]. ( Dong, H; Lu, FE; Wu, S, 2011) |
| "To explore the direct contribution of dexamethasone (Dex) for insulin resistance inducing in thecal cells and effects of berberine (Ber) and puerarin (Pue)." | 7.75 | [Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells]. ( Gao, L; Kuang, HY; Li, W, 2009) |
| "The purpose of the study is to investigate the effect of 8-hydroxy-dihydroberberine on insulin resistance induced by high free fatty acid (FFA) and high glucose in 3T3-L1 adipocytes and its possible molecular mechanism." | 7.75 | [8-hydroxy-dihydroberberine ameliorated insulin resistance induced by high FFA and high glucose in 3T3-L1 adipocytes]. ( Chen, G; Dong, H; Lu, FE; Wang, ZS; Wei, SC; Xu, LJ; Yi, P; Zou, X, 2009) |
| "The effects of berberine on the expression of hepatocyte nuclear factor-4alpha (HNF-4alpha) in liver of rats with fructose-induced insulin resistance and the molecular mechanism of berberine preventing insulin resistance were investigated." | 7.74 | Effect of berberine on expression of hepatocyte nuclear factor-4alpha in rats with fructose-induced insulin resistance. ( Gao, Z; Leng, S; Lu, F; Wang, K; Xie, M; Xu, L, 2008) |
| "5 mmol/L) to induce insulin resistance and intervened with berberine." | 7.74 | [Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes]. ( Chen, G; Lu, FE; Yi, P, 2007) |
| "To investigate the effects and molecular mechanisms of berberine on improving insulin resistance induced by free fatty acids (FFAs) in 3T3-L1 adipocytes." | 7.74 | Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. ( Chen, G; Dong, H; Lu, FE; Wang, KF; Xu, LJ; Yi, P, 2008) |
| "In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy." | 6.82 | Berberine in Non-Alcoholic Fatty Liver Disease-A Review. ( Koperska, A; Moszak, M; Szulińska, M; Wesołek, A, 2022) |
| "Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer." | 6.77 | A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. ( Deng, H; Guan, Y; Liang, K; Ma, Y; Sui, M; Wang, A; Wei, W; Zhang, H; Zhang, Y; Zhao, H, 2012) |
| "Berberine is an alkaloid found in plants." | 6.72 | Berberine in the Treatment of Diabetes Mellitus: A Review. ( Baska, A; Gałązka, P; Leis, K, 2021) |
| "Berberine (BBR) has been shown to improve T2DM with IR in a number of ways." | 6.61 | Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review. ( Li, H; Li, S; Liu, B; Wang, Y; Yan, A; Yan, Y, 2019) |
| " The bioavailability of berberine is extremely low, suggesting that it may play a role in lowering blood sugar and lipid by regulating intestinal flora." | 6.55 | [Berberine regulates type 2 diabetes mellitus related with insulin resistance]. ( He, JZ; Li, C; Xu, X; Zhou, XD, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is a globally observed metabolic disease with high prevalence both in adults and children." | 6.53 | The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. ( Bian, H; Gao, X; Zhu, X, 2016) |
| "In this double-blind, placebo-controlled trial, adults living with HIV under virological suppression and metabolic syndrome received either berberine 500 mg TID or placebo for 20 weeks." | 5.69 | Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection. ( Alvarez-Zavala, M; Andrade-Villanueva, JF; González-Hernández, LA; Martínez-Ayala, P; Méndez-Clemente, AS; Navarro-Lara, SA; Ruiz-Herrera, VV; Sánchez-Reyes, K; Toscano-Piña, M; Valle-Rodríguez, A, 2023) |
| "Berberine (BBR) has many pharmacological properties and is used as an insulin sensitizer." | 5.62 | Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. ( Li, XL; Shen, HR; Xu, X, 2021) |
| " A highly bioavailable berberine formulation termed Huang-Gui solid dispersion (HGSD), is a preparation of berberine coupled to sodium caprate and this markedly improving berberines bioavailability." | 5.56 | Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance ( Chen, L; Guan, F; Hatch, GM; Lv, X; Meng, Z; Yang, X; Yu, Y; Zhang, M; Zhang, Y, 2020) |
| "Insulin resistance is considered one of risk reasons which lead to several metabolic diseases." | 5.51 | Berberine chloride ameliorated PI3K/Akt-p/SIRT-1/PTEN signaling pathway in insulin resistance syndrome induced in rats. ( El-Kott, AF; El-Sayed, M; El-Zeftawy, M; ElBealy, ER; Elguindy, N; Ghareeb, D; Mahmoud, S; Saad, R, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome." | 5.46 | Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. ( Cang, Z; Lu, Y; Nie, X; Sun, H; Wang, N; Zhao, L, 2017) |
| "Treatment with berberine regulated BMP4 transcriptional pathways and brown adipose tissue transcriptional pathways and induced the gene mRNA expression of brown adipose tissue-specific genes in VWAT to develop browning gene phenotype of white adipose tissues, and then improved fat-induced insulin resistance." | 5.43 | [Regulations of berberine on gene expression of BMP4 transcriptional pathways to improve visceral white adipose tissues insulin resistance in type 2 diabetic hamsters]. ( Gao, ZN; Huang, L; Li, GS; Li, XY; Liu, XH; Liu, YL, 2016) |
| "Berberine (BBR) is an isoquinoline alkaloid extracted from Rhizoma coptidis and has been used for treating type 2 diabetes mellitus (T2DM) in China." | 5.43 | Berberine relieves insulin resistance via the cholinergic anti-inflammatory pathway in HepG2 cells. ( Fang, K; Li, F; Wang, DK; Wang, KF; Zhao, YB; Zou, X, 2016) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 5.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "Berberine (BBR) has been reported in several studies in cell and animal models." | 5.42 | Protective effects of berberine on high fat-induced kidney damage by increasing serum adiponectin and promoting insulin sensitivity. ( Cha, Y; Chen, Z; Ding, H; Huang, X; Liu, J; Sheng, L; Wang, F; Wu, U; Xu, J, 2015) |
| " The aim of this one-group pretest-post-test explanatory study was to evaluate, in normal-overweight PCOS women with normal menses, the effectiveness of berberine on: Insulin resistance (IR) by Homeostasis Model Assessment (HOMA); Inflammation by C-Reactive Protein (CRP), Tumor Necrosis Factor α (TNF-α); Lipid metabolism; Sex hormone profile and symptoms correlated to hyperandrogenism, such as acne, by Global Acne Grading System (GAGS) and Cardiff Acne Disability Index (CADI); Body composition by DXA." | 5.41 | Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study. ( Allegrini, P; Bernardinelli, L; Fazia, T; Gasparri, C; Giacosa, A; Perna, S; Peroni, G; Petrangolini, G; Riva, A; Rondanelli, M, 2021) |
| "Berberine has been reported to have antidiabetic properties." | 5.36 | Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. ( Huang, L; Li, G; Liu, X; Liu, Y; Ma, C; Qin, C; Zhu, H, 2010) |
| "In animal models, treatment of type 2 diabetes mellitus rats with BBR lowered fasting blood glucose and fasting serum insulin, increased insulin sensitivity, and elevated InsR mRNA as well as PKC activity in the liver." | 5.35 | Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. ( Jiang, JD; Kong, WJ; Li, ZR; Pan, HN; Shan, N; Si, SY; Song, DQ; Wang, YM; Wei, J; Xue, R; Yang, P; You, XF; Zhang, H; Zhao, LX; Zhao, W; Zhou, ZX, 2009) |
| "Berberine treatment increased the glucose consumption and insulin-stimulated glucose uptake in normal cells and improved glucose uptake in the FFA-induced insulin-resistant cells." | 5.35 | Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. ( Chen, Y; Li, Y; Sun, C; Wang, Y; Wen, Y, 2009) |
| " The aim of this study was to evaluate the potential beneficial effects of Armolipid Plus (AP) (berberine 500 mg, red yest rice, monacolin K 3 mg and policosanol 10 mg) on insulin resistance, lipid profile, particularly on small and dense LDL cholesterol (sdLDL-C), representing the most atherogenic components, as well as its effects on high sensitivity C-reactive protein, a notable marker of cardiovascular risk, blood pressure and cardiac remodeling in subjects affected by MetS, with left ventricular hypertrophy." | 5.30 | Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. ( Battista, F; Bonaduce, D; Bosso, G; Brambilla, N; D'Amato, M; Fazio, V; Galletti, F; Gentile, M; Giacovelli, G; Mercurio, V; Pucci, G; Schillaci, G; Vitalini, C, 2019) |
| " This randomized controlled trial aims to evaluate the efficacy and safety of berberine in the treatment of patients with polycystic ovary syndrome." | 5.22 | The effect of berberine on insulin resistance in women with polycystic ovary syndrome: detailed statistical analysis plan (SAP) for a multicenter randomized controlled trial. ( Chai, QY; Liu, JP; Ma, HL; Sun, J; Wu, XK; Zhang, K; Zhang, Y; Zhang, YJ, 2016) |
| "The aim of this study was to evaluate the effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion." | 5.17 | Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ( Espinel-Bermúdez, MC; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA, 2013) |
| "We postulate that women with PCOS will have improved insulin resistance following berberine administration." | 5.17 | Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. ( Hou, L; Kuang, H; Li, Y; Ma, H; Ng, EH; Wu, X; Zhang, Y, 2013) |
| " We evaluated the effects of a nutraceutical combination (NC), consisting of 500 mg berberine, 200mg red yeast rice and 10mg policosanols, on cholesterol levels and endothelial function in patients with hypercholesterolemia." | 5.14 | Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. ( Affuso, F; Fazio, S; Micillo, F; Ruvolo, A; Saccà, L, 2010) |
| "The objective of the study was to evaluate the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia." | 5.13 | Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. ( Hong, J; Huo, L; Li, X; Liu, W; Ning, G; Ren, G; Wang, M; Wu, P; Yang, J; Zhang, Y; Zhu, N; Zou, D, 2008) |
| "Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc." | 5.12 | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. ( Cai, B; Chen, Q; Wang, S; Xu, Z, 2021) |
| "Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone." | 5.12 | Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. ( He, B; Xing, C; Zhang, J; Zhao, H, 2021) |
| "This study provides a critical overview of experimental studies in vitro, in humans, and in animals that evaluated the efficacy of Berberine and its effect on management of obesity and the related metabolic consequences." | 5.05 | The effect of Berberine on weight loss in order to prevent obesity: A systematic review. ( Al-Thawadi, S; Alalwan, TA; Gasparri, C; Ilyas, Z; Infantino, V; Perna, S; Peroni, G; Petrangolini, G; Riva, A; Rondanelli, M, 2020) |
| " Berberine has been used to treat obesity, diabetes mellitus, atherosclerosis, and metabolic diseases in China." | 5.05 | Effects of Berberine on the Gastrointestinal Microbiota. ( Chen, F; Liao, Y; Sun, X; Wang, L; Wu, X; Wu, Z; Yang, R; Zhang, L; Zhu, Z, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 4.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| " Among these compounds, berberine, an isoquinoline alkaloid derived from plants of the generis Berberis, has been recognized as being capable of decreasing oxidative stress, LDL, triglycerides, and insulin resistance and of improving the mood." | 4.91 | Potential benefits of berberine in the management of perimenopausal syndrome. ( Caliceti, C; Cicero, AF; Rizzo, P, 2015) |
| "To investigate whether astragalus polysaccharides (APS) combined with berberine (BBR) can reduce high-fat diet (HFD)-induced obesity in mice." | 4.31 | Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice. ( Feng, WW; Gao, H; Liu, J; Tang, YP; Wang, WX; Yan, D; Yue, SJ; Zhang, L, 2023) |
| "Co-administration of metformin (250 mg/kg) with berberine (125 mg/kg) could not only further improve insulin sensitivity, but also demonstrate different alterations on gut microbial communities than that of their individual treatment in db/db mice." | 4.12 | Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice. ( Kong, APS; Li, D; Li, Z; Lyu, Y; Ming, X; Shaw, PC; Yuan, X; Zhang, C; Zhang, J; Zuo, Z, 2022) |
| "The aim of this study was to investigate the effects of berberine on polycystic ovary syndrome (PCOS) with insulin resistance (IR)." | 4.02 | Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites. ( Li, XL; Shen, HR; Xu, X; Ye, D, 2021) |
| "Berberine is a natural isoquinoline alkaloid present in various herbs and is effective against metabolic syndrome in the pre-diabetic stage and high insulin resistance." | 4.02 | WJCPR11 reverses the TNF-α-induced inhibition of adipocyte differentiation and glucose uptake. ( Han, Y; Kim, MS; Lee, KY; Nam, SW, 2021) |
| " It is widely reported that berberine (BBR) has an anti-inflammatory effect and can reduce glucose and lipid accumulation, whereas ginsenoside Rb1 (Rb1) has been shown to have a significant inhibitory effect on insulin resistance and lipid peroxidation." | 4.02 | Synergetic protective effect of berberine and ginsenoside Rb1 against tumor necrosis factor alpha-induced inflammation in adipocytes. ( Cai, Z; Chen, Y, 2021) |
| "Berberine has been found to exhibit an array of pharmacological activities relating to the lowering of blood glucose and the treatment of polycystic ovarian syndrome (PCOS)." | 3.96 | Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. ( Fang, J; Li, F; Liu, X; Liu, Z; Shan, Y; Wang, Y; Zhang, N; Zhao, H; Zhuang, L, 2020) |
| "To study the role of selected serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome (PCOS)." | 3.96 | The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome. ( Ai, W; Duan, Y; Kuang, H; Li, D; Li, M; Li, W; Liu, S; Liu, X; Shao, M; Wang, Y; Xu, Y, 2020) |
| "To elucidate the protective effect of berberine on olanzapine induced-metabolic syndrome." | 3.91 | Berberine attenuates olanzapine induced-metabolic syndrome. ( Al-Gareeb, AI; Al-Kuraishy, HM; Al-Naimi, MS; Rasheed, HA, 2019) |
| "Diabetogenesis triggered by arsenic contributed to the mitochondrial ROS overproduction, impaired complex II activity, glucose homeostasis, glucose tolerance and insulin sensitivity." | 3.91 | SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification. ( Javadipour, M; Keshtzar, E; Khodayar, MJ; Rezaei, M, 2019) |
| "Berberine, a natural compound extracted from several Chinese herbs including Coptis chinensis, has been shown to have anti-obesity effects and prevents insulin resistance in high-fat diet (HFD)-fed obese rats by modulating the gut microbiota; however, the molecular mechanisms underlying these activities remain unknown." | 3.88 | Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. ( Hou, L; Li, S; Liu, D; Liu, Y; Tian, H; Zhang, Y; Zhao, T, 2018) |
| "The results showed that administration of berberine for 6 months significantly improved cognitive deficits and insulin resistance in naturally aging rats (p<0." | 3.88 | Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats. ( Chen, L; Guan, F; Guan, Y; Li, J; Lv, X; Teng, F; Xu, J; Yu, Y; Zhang, M; Zhao, Y, 2018) |
| " Berberine (BBR) has been reported to improve insulin sensitivity in mice with hepatic steatosis." | 3.88 | Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes. ( Du, XL; Fang, ZY; Fu, SP; Li, XB; Li, XW; Liu, GW; Peng, ZC; Shi, Z; Wang, Z; Zhao, CX, 2018) |
| "To investigate the hypoglycemic effects of baicalin, berberine, puerarin and liquiritin on the insulin resistance (IR) cells." | 3.88 | [Differentiated hypoglycemic effects of baicalin, berberine and puerarin on insulin-resistance HepG2 cells]. ( Tu, J; Zhou, XM; Zhu, SL, 2018) |
| " In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1β (IL-1β) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue." | 3.85 | Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement. ( Feng, L; Liu, H; Ma, Y; Shen, Y; Sun, Y; Wu, X; Xu, F; Xu, G; Xu, Q; Zhang, X; Zhou, H, 2017) |
| "Berberine improves diabetic vascular insulin sensitivity and mesenteric vasodilatation by up-regulating insulin receptor-mediated signalling in diabetic rats." | 3.83 | Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats. ( Dong, L; Dong, MQ; Gao, F; Geng, FH; Li, GH; Zhang, P; Zhang, X; Zhang, Y; Zhao, ZJ, 2016) |
| "Berberine could reduce weight gain and lipolysis in the high-fat diet-fed group." | 3.83 | Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats. ( Cang, Z; Cheng, J; Lu, Y; Nie, X; Sun, H; Wang, N; Xia, F; Zhai, H; Zhao, L; Zhu, C, 2016) |
| "To explore the possible mechanism of berberine improve insulin resistance in skeletal muscle of obese rats." | 3.81 | [Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance]. ( Bai, XH; Chen, J; Mu, DZ; Yao, YJ; Zhang, DS, 2015) |
| " Berberine (BBR) is a plant alkaloid which promotes hypoglycemia via increasing insulin sensitivity in peripheral tissues." | 3.79 | Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase. ( Chang, W; Chen, L; Du, H; Hatch, GM; Li, J; Meng, Z; Wei, S; Zhang, M, 2013) |
| "Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance." | 3.78 | Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. ( Duarte, FV; Gomes, AP; Hubbard, BP; Jones, JG; Nunes, P; Palmeira, CM; Rolo, AP; Sinclair, DA; Teodoro, JS; Varela, AT, 2012) |
| "Berberine exerts insulin resistance-improving effects, the underlying mechanism of which is not well understood." | 3.78 | A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats. ( Gao, FY; Gu, JJ; Zhao, TY, 2012) |
| "Theca cells with dexamethasone-induced insulin resistance showed defective glucose uptake and excessive testosterone production, both of which were effectively antagonized by berberine." | 3.77 | Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. ( Baillargeon, JP; Han, F; Hou, L; Kuang, H; Li, W; Wang, Y; Wu, X; Zhao, L, 2011) |
| "Berberine, a major isoquinoline alkaloid present in Chinese herb Rhizoma coptidis, is a potent inhibitor of inflammation and has anti-diabetic activity." | 3.77 | Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. ( Huang, F; Li, L; Liu, B; Liu, K; Lou, T; Xi, Z; Zhang, Z, 2011) |
| "This study was performed to investigate the molecular mechanism and the therapeutic effect of berberine on nonalcoholic fatty liver disease (NAFLD)." | 3.77 | Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. ( Hua, YQ; Ji, G; Liu, T; Xing, LJ; Zhang, L; Zheng, PY, 2011) |
| "To explore the effects of berberine on the pancreatic 13 cell apoptosis in rats with insulin resistance (IR)." | 3.77 | [Effects of berberine on the pancreatic beta cell apoptosis in rats with insulin resistance]. ( Dong, H; Lu, FE; Wu, S, 2011) |
| "To investigate the functional and metabolic alterations in cultured insulin resistant ovary model in vitro, and to observe the effect of berberine (Ber, a Chinese medical monomer) in improving insulin resistance (IR)." | 3.76 | [Controlling effect of berberine on in vitro synthesis and metabolism of steroid hormones in insulin resistant ovary]. ( Li, W; Liu, YC; Wang, XX, 2010) |
| " Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR)." | 3.76 | Berberine inhibits PTP1B activity and mimics insulin action. ( Chen, C; Huang, C; Zhang, Y, 2010) |
| "To explore the direct contribution of dexamethasone (Dex) for insulin resistance inducing in thecal cells and effects of berberine (Ber) and puerarin (Pue)." | 3.75 | [Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells]. ( Gao, L; Kuang, HY; Li, W, 2009) |
| "The purpose of the study is to investigate the effect of 8-hydroxy-dihydroberberine on insulin resistance induced by high free fatty acid (FFA) and high glucose in 3T3-L1 adipocytes and its possible molecular mechanism." | 3.75 | [8-hydroxy-dihydroberberine ameliorated insulin resistance induced by high FFA and high glucose in 3T3-L1 adipocytes]. ( Chen, G; Dong, H; Lu, FE; Wang, ZS; Wei, SC; Xu, LJ; Yi, P; Zou, X, 2009) |
| "The effects of berberine on the expression of hepatocyte nuclear factor-4alpha (HNF-4alpha) in liver of rats with fructose-induced insulin resistance and the molecular mechanism of berberine preventing insulin resistance were investigated." | 3.74 | Effect of berberine on expression of hepatocyte nuclear factor-4alpha in rats with fructose-induced insulin resistance. ( Gao, Z; Leng, S; Lu, F; Wang, K; Xie, M; Xu, L, 2008) |
| "5 mmol/L) to induce insulin resistance and intervened with berberine." | 3.74 | [Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes]. ( Chen, G; Lu, FE; Yi, P, 2007) |
| "To investigate the effects and molecular mechanisms of berberine on improving insulin resistance induced by free fatty acids (FFAs) in 3T3-L1 adipocytes." | 3.74 | Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. ( Chen, G; Dong, H; Lu, FE; Wang, KF; Xu, LJ; Yi, P, 2008) |
| "It is confirmed that berberin could raise insulin sensitivity of high fat diet rats similar to metformin." | 3.69 | [Experimental study on berberin raised insulin sensitivity in insulin resistance rat models]. ( Gao, CR; Huang, QL; Zhang, JQ, 1997) |
| "In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy." | 2.82 | Berberine in Non-Alcoholic Fatty Liver Disease-A Review. ( Koperska, A; Moszak, M; Szulińska, M; Wesołek, A, 2022) |
| "Nutraceuticals (NUT) are forms of compounds with biological activity commonly used to improve health in dosage largely exceeding those obtainable in food." | 2.80 | Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. ( Esposito, G; Izzo, R; Manzi, MV; Rozza, F; Santoro, M; Schiattarella, GG; Serino, F; Stabile, E; Trimarco, B; Trimarco, V, 2015) |
| "Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer." | 2.77 | A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. ( Deng, H; Guan, Y; Liang, K; Ma, Y; Sui, M; Wang, A; Wei, W; Zhang, H; Zhang, Y; Zhao, H, 2012) |
| "Berberine is an alkaloid found in plants." | 2.72 | Berberine in the Treatment of Diabetes Mellitus: A Review. ( Baska, A; Gałązka, P; Leis, K, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world." | 2.72 | Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. ( Li, L; Xie, J; Zhao, L, 2021) |
| "Berberine (BBR) has been shown to improve T2DM with IR in a number of ways." | 2.61 | Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review. ( Li, H; Li, S; Liu, B; Wang, Y; Yan, A; Yan, Y, 2019) |
| " While lifestyle approaches, such as with the Mediterranean diet, may prove to be too complex for the single patient, better knowledge of selected nutraceuticals and more appropriate formulations leading to improved bioavailability will certainly widen the use of these agents, already in large use for the management of these very frequent patient groups." | 2.55 | Nutraceutical approaches to metabolic syndrome. ( Calabresi, L; Pavanello, C; Ruscica, M; Sirtori, CR, 2017) |
| " The bioavailability of berberine is extremely low, suggesting that it may play a role in lowering blood sugar and lipid by regulating intestinal flora." | 2.55 | [Berberine regulates type 2 diabetes mellitus related with insulin resistance]. ( He, JZ; Li, C; Xu, X; Zhou, XD, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is a globally observed metabolic disease with high prevalence both in adults and children." | 2.53 | The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. ( Bian, H; Gao, X; Zhu, X, 2016) |
| "Berberine is a potent oral hypoglycemic agent with a good effect on lipid metabolism." | 2.50 | Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. ( Derosa, G; Maffioli, P, 2014) |
| "Berberine is an alkaloid that is highly concentrated in the roots, rhizomes, and stem bark of various plants." | 2.48 | Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. ( Cicero, AF; Tartagni, E, 2012) |
| "Berberine treatment attenuates hippocampal insulin resistance and improves cognitive function." | 1.91 | Simulated weightlessness induces hippocampal insulin resistance and cognitive impairment. ( Chen, J; Dong, L; Gao, F; Kou, Z; Kuang, F; Li, G; Li, J; Xue, C; Yang, H; Zhang, J; Zhang, S; Zhang, X, 2023) |
| "Postprandial hyperglycemia is an important causative factor of type 2 diabetes mellitus, and permanent localization of intestinal GLUT2 in the brush border membrane is an important reason of postprandial hyperglycemia." | 1.62 | Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. ( Dong, L; Li, J; Yang, E; Yang, H; Zhang, M, 2021) |
| "Berberine (BBR) has many pharmacological properties and is used as an insulin sensitizer." | 1.62 | Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. ( Li, XL; Shen, HR; Xu, X, 2021) |
| "Berberine was used to uncover the mechanisms for the treatment of hyperinsulinemia in IR model." | 1.62 | Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway. ( Bao, Y; Chen, Q; Han, Y; Liu, C; Liu, W; Liu, X; Wang, J; Wu, N; Ye, Y; Yu, Y, 2021) |
| "Berberine has been reported to have pharmacological activity in adipose tissue to anti-obesity, while the mechanism remains unclear." | 1.62 | Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway. ( Cao, L; He, Z; Jiang, X; Kong, J; Li, N; Ma, G; Song, X; Wang, Z; Wen, D; Xu, Y; Yang, F; Yu, T; Yu, Y; Zheng, L, 2021) |
| " A highly bioavailable berberine formulation termed Huang-Gui solid dispersion (HGSD), is a preparation of berberine coupled to sodium caprate and this markedly improving berberines bioavailability." | 1.56 | Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance ( Chen, L; Guan, F; Hatch, GM; Lv, X; Meng, Z; Yang, X; Yu, Y; Zhang, M; Zhang, Y, 2020) |
| "Insulin resistance is considered one of risk reasons which lead to several metabolic diseases." | 1.51 | Berberine chloride ameliorated PI3K/Akt-p/SIRT-1/PTEN signaling pathway in insulin resistance syndrome induced in rats. ( El-Kott, AF; El-Sayed, M; El-Zeftawy, M; ElBealy, ER; Elguindy, N; Ghareeb, D; Mahmoud, S; Saad, R, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome." | 1.46 | Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. ( Cang, Z; Lu, Y; Nie, X; Sun, H; Wang, N; Zhao, L, 2017) |
| "Treatment with berberine regulated BMP4 transcriptional pathways and brown adipose tissue transcriptional pathways and induced the gene mRNA expression of brown adipose tissue-specific genes in VWAT to develop browning gene phenotype of white adipose tissues, and then improved fat-induced insulin resistance." | 1.43 | [Regulations of berberine on gene expression of BMP4 transcriptional pathways to improve visceral white adipose tissues insulin resistance in type 2 diabetic hamsters]. ( Gao, ZN; Huang, L; Li, GS; Li, XY; Liu, XH; Liu, YL, 2016) |
| "Berberine (BBR) is an isoquinoline alkaloid extract that has shown promise as a hypoglycemic agent in the management of diabetes in animal and human studies." | 1.43 | Berberine treatment attenuates the palmitate-mediated inhibition of glucose uptake and consumption through increased 1,2,3-triacyl-sn-glycerol synthesis and accumulation in H9c2 cardiomyocytes. ( Chang, W; Chen, L; Hatch, GM, 2016) |
| "Berberine (BBR) is an isoquinoline alkaloid extracted from Rhizoma coptidis and has been used for treating type 2 diabetes mellitus (T2DM) in China." | 1.43 | Berberine relieves insulin resistance via the cholinergic anti-inflammatory pathway in HepG2 cells. ( Fang, K; Li, F; Wang, DK; Wang, KF; Zhao, YB; Zou, X, 2016) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 1.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "Berberine (BBR) has been reported in several studies in cell and animal models." | 1.42 | Protective effects of berberine on high fat-induced kidney damage by increasing serum adiponectin and promoting insulin sensitivity. ( Cha, Y; Chen, Z; Ding, H; Huang, X; Liu, J; Sheng, L; Wang, F; Wu, U; Xu, J, 2015) |
| "Berberine is an isoquinoline alkaloid widely used in Asian countries as a traditional medicine." | 1.38 | Possible therapeutic potential of berberine in diabetic osteopathy. ( Bhutada, PS; Kaulaskar, SV; Rahigude, AB, 2012) |
| "Berberine has been shown to have insulin-sensitizing effect, but the molecular mechanism underlying remains elusive." | 1.36 | Berberine modulates insulin signaling transduction in insulin-resistant cells. ( Chan, JC; Cheung, SC; Ho, SK; Lan, LL; Liu, LZ; Tong, PC; Xu, HX, 2010) |
| "Berberine has been reported to have antidiabetic properties." | 1.36 | Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. ( Huang, L; Li, G; Liu, X; Liu, Y; Ma, C; Qin, C; Zhu, H, 2010) |
| "In animal models, treatment of type 2 diabetes mellitus rats with BBR lowered fasting blood glucose and fasting serum insulin, increased insulin sensitivity, and elevated InsR mRNA as well as PKC activity in the liver." | 1.35 | Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. ( Jiang, JD; Kong, WJ; Li, ZR; Pan, HN; Shan, N; Si, SY; Song, DQ; Wang, YM; Wei, J; Xue, R; Yang, P; You, XF; Zhang, H; Zhao, LX; Zhao, W; Zhou, ZX, 2009) |
| "Berberine treatment increased the glucose consumption and insulin-stimulated glucose uptake in normal cells and improved glucose uptake in the FFA-induced insulin-resistant cells." | 1.35 | Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. ( Chen, Y; Li, Y; Sun, C; Wang, Y; Wen, Y, 2009) |
| "Berberine treatment resulted in increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 adipocytes and L6 myotubes, increased GLUT4 translocation in L6 cells in a phosphatidylinositol 3' kinase-independent manner, and reduced lipid accumulation in 3T3-L1 adipocytes." | 1.33 | Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. ( Cho, HJ; Gosby, A; Hohnen-Behrens, C; James, DE; Kim, CT; Kim, JB; Kim, KH; Kim, WS; Kraegen, EW; Lee, CH; Lee, YS; Oh, WK; Shen, Y; Ye, JM; Yoon, MJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.84) | 18.2507 |
| 2000's | 11 (9.24) | 29.6817 |
| 2010's | 66 (55.46) | 24.3611 |
| 2020's | 41 (34.45) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, HR | 2 |
| Xu, X | 4 |
| Ye, D | 1 |
| Li, XL | 2 |
| Nam, SW | 1 |
| Kim, MS | 1 |
| Han, Y | 2 |
| Lee, KY | 1 |
| Rondanelli, M | 2 |
| Riva, A | 2 |
| Petrangolini, G | 2 |
| Allegrini, P | 1 |
| Giacosa, A | 1 |
| Fazia, T | 1 |
| Bernardinelli, L | 1 |
| Gasparri, C | 2 |
| Peroni, G | 2 |
| Perna, S | 2 |
| Cai, Z | 1 |
| Chen, Y | 4 |
| Yue, SJ | 2 |
| Wang, WX | 1 |
| Zhang, L | 4 |
| Liu, J | 4 |
| Feng, WW | 1 |
| Gao, H | 1 |
| Tang, YP | 1 |
| Yan, D | 2 |
| Zhang, M | 6 |
| Yang, H | 2 |
| Yang, E | 1 |
| Li, J | 7 |
| Dong, L | 3 |
| Xia, QS | 1 |
| Wu, F | 1 |
| Wu, WB | 1 |
| Dong, H | 9 |
| Huang, ZY | 1 |
| Xu, L | 2 |
| Lu, FE | 8 |
| Gong, J | 1 |
| Li, Y | 7 |
| Chen, X | 1 |
| Yu, D | 1 |
| Jiang, R | 1 |
| Kou, X | 1 |
| Sheng, L | 2 |
| Liu, Y | 4 |
| Song, Y | 1 |
| Lyu, Y | 1 |
| Li, D | 3 |
| Yuan, X | 1 |
| Li, Z | 4 |
| Zhang, J | 3 |
| Ming, X | 1 |
| Shaw, PC | 1 |
| Zhang, C | 2 |
| Kong, APS | 1 |
| Zuo, Z | 1 |
| Koperska, A | 1 |
| Wesołek, A | 1 |
| Moszak, M | 1 |
| Szulińska, M | 1 |
| Urasaki, Y | 1 |
| Le, TT | 1 |
| He, Q | 3 |
| Guo, Y | 3 |
| Gong, M | 3 |
| Xia, Q | 3 |
| Lu, F | 4 |
| Wang, D | 3 |
| Cheng, J | 2 |
| Ma, X | 1 |
| Yan, G | 1 |
| Yu, Q | 1 |
| Huang, Z | 1 |
| Lin, G | 1 |
| Li, M | 3 |
| Guan, F | 3 |
| Su, Z | 1 |
| Yan, F | 1 |
| Xie, Q | 1 |
| Bellavite, P | 1 |
| Fazio, S | 3 |
| Affuso, F | 2 |
| Ruiz-Herrera, VV | 1 |
| Navarro-Lara, SA | 1 |
| Andrade-Villanueva, JF | 1 |
| Alvarez-Zavala, M | 1 |
| Sánchez-Reyes, K | 1 |
| Toscano-Piña, M | 1 |
| Méndez-Clemente, AS | 1 |
| Martínez-Ayala, P | 1 |
| Valle-Rodríguez, A | 1 |
| González-Hernández, LA | 1 |
| Xue, C | 1 |
| Li, G | 2 |
| Kuang, F | 1 |
| Chen, J | 2 |
| Zhang, S | 1 |
| Gao, F | 2 |
| Kou, Z | 1 |
| Zhang, X | 7 |
| Li, Q | 1 |
| Zhao, S | 1 |
| Sun, L | 1 |
| Yin, Z | 1 |
| Wang, X | 1 |
| Li, X | 3 |
| Iwakiri, Y | 1 |
| Han, J | 1 |
| Duan, Y | 3 |
| Wang, Y | 9 |
| Yan, A | 1 |
| Li, S | 2 |
| Liu, B | 2 |
| Li, H | 1 |
| Yan, Y | 1 |
| El-Zeftawy, M | 1 |
| Ghareeb, D | 1 |
| ElBealy, ER | 1 |
| Saad, R | 1 |
| Mahmoud, S | 1 |
| Elguindy, N | 1 |
| El-Kott, AF | 1 |
| El-Sayed, M | 1 |
| Al-Naimi, MS | 1 |
| Rasheed, HA | 1 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Gong, W | 1 |
| Lv, S | 1 |
| Qu, H | 1 |
| He, Y | 2 |
| Zhang, N | 1 |
| Liu, X | 5 |
| Zhuang, L | 1 |
| Zhao, H | 3 |
| Shan, Y | 1 |
| Liu, Z | 2 |
| Li, F | 2 |
| Fang, J | 1 |
| Ilyas, Z | 1 |
| Al-Thawadi, S | 1 |
| Alalwan, TA | 1 |
| Infantino, V | 1 |
| Qian, S | 1 |
| Ma, L | 1 |
| Peng, S | 1 |
| Xu, Y | 3 |
| Wu, K | 1 |
| Shen, S | 1 |
| Sun, Y | 3 |
| Ye, J | 2 |
| Xu, XH | 1 |
| Hu, Q | 1 |
| Zhou, LS | 1 |
| Xu, LJ | 5 |
| Zou, X | 4 |
| Yi, P | 5 |
| Dong, ZH | 1 |
| Lin, HY | 1 |
| Chen, FL | 1 |
| Che, XQ | 1 |
| Bi, WK | 1 |
| Shi, SL | 1 |
| Wang, J | 2 |
| Gao, L | 2 |
| He, Z | 2 |
| Zhao, JJ | 1 |
| Kuang, H | 3 |
| Ai, W | 1 |
| Li, W | 5 |
| Liu, S | 1 |
| Shao, M | 1 |
| Meng, Z | 2 |
| Yu, Y | 4 |
| Zhang, Y | 10 |
| Yang, X | 1 |
| Lv, X | 2 |
| Hatch, GM | 3 |
| Chen, L | 4 |
| Cheng, C | 1 |
| Chen, D | 1 |
| Mirzaee, F | 1 |
| Razmjouei, P | 1 |
| Shahrahmani, H | 1 |
| Vafisani, F | 1 |
| Najaf Najafi, M | 1 |
| Ghazanfarpour, M | 1 |
| Wang, S | 1 |
| Xu, Z | 1 |
| Cai, B | 1 |
| Chen, Q | 2 |
| Baska, A | 1 |
| Leis, K | 1 |
| Gałązka, P | 1 |
| Wu, X | 6 |
| Yang, R | 1 |
| Chen, F | 1 |
| Liao, Y | 1 |
| Zhu, Z | 1 |
| Wu, Z | 1 |
| Sun, X | 1 |
| Wang, L | 2 |
| Yu, J | 1 |
| Ding, C | 1 |
| Hua, Z | 1 |
| Jiang, X | 2 |
| Wang, C | 1 |
| Fan, CF | 1 |
| Guo, YS | 1 |
| Wang, JH | 1 |
| Li, P | 1 |
| Zhang, HL | 1 |
| Wu, N | 1 |
| Liu, W | 2 |
| Ye, Y | 1 |
| Bao, Y | 1 |
| Liu, C | 1 |
| Zhang, SW | 1 |
| Zhou, J | 1 |
| Gober, HJ | 1 |
| Leung, WT | 1 |
| Xie, J | 1 |
| Li, L | 2 |
| Zhao, L | 5 |
| Zhang, JH | 2 |
| Yang, HZ | 1 |
| Su, H | 2 |
| Song, J | 2 |
| Bai, Y | 2 |
| Deng, L | 2 |
| Feng, CP | 2 |
| Guo, HX | 2 |
| Gao, X | 6 |
| Gu, Y | 3 |
| Zhen, Z | 2 |
| Lu, Y | 4 |
| Zhang, JF | 1 |
| Xu, XY | 1 |
| Jin, C | 1 |
| Zheng, JF | 1 |
| Behl, T | 1 |
| Gupta, A | 1 |
| Sehgal, A | 1 |
| Sharma, S | 1 |
| Singh, S | 1 |
| Sharma, N | 1 |
| Diaconu, CC | 1 |
| Rahdar, A | 1 |
| Hafeez, A | 1 |
| Bhatia, S | 1 |
| Al-Harrasi, A | 1 |
| Bungau, S | 1 |
| Xing, C | 1 |
| He, B | 1 |
| Yang, C | 1 |
| Zhu, JZ | 1 |
| Lopez, E | 1 |
| Zhang, T | 1 |
| Tong, Q | 1 |
| Peng, C | 2 |
| Lin, LG | 1 |
| Yu, T | 1 |
| Ma, G | 1 |
| Zheng, L | 1 |
| Yang, F | 1 |
| Wang, Z | 2 |
| Li, N | 1 |
| Song, X | 1 |
| Wen, D | 1 |
| Kong, J | 1 |
| Cao, L | 1 |
| Ong, M | 1 |
| Peng, J | 1 |
| Jin, X | 1 |
| Qu, X | 1 |
| Sirtori, CR | 1 |
| Pavanello, C | 1 |
| Calabresi, L | 1 |
| Ruscica, M | 1 |
| Li, C | 1 |
| He, JZ | 1 |
| Zhou, XD | 1 |
| Li, GS | 2 |
| Liu, XH | 2 |
| Li, XY | 2 |
| Gao, ZN | 1 |
| Huang, L | 3 |
| Liu, YL | 2 |
| Tu, J | 2 |
| Luo, XX | 1 |
| Li, BT | 1 |
| Xu, GL | 1 |
| Cao, H | 1 |
| Liao, S | 1 |
| Zhong, W | 1 |
| Xiao, X | 1 |
| Zhu, J | 1 |
| Feng, Y | 1 |
| Liu, D | 2 |
| Hou, L | 3 |
| Tian, H | 1 |
| Zhao, T | 1 |
| Zhao, Y | 2 |
| Teng, F | 1 |
| Guan, Y | 2 |
| Xu, J | 3 |
| Shi, Z | 1 |
| Li, XB | 1 |
| Peng, ZC | 1 |
| Fu, SP | 1 |
| Zhao, CX | 1 |
| Du, XL | 1 |
| Fang, ZY | 1 |
| Liu, GW | 1 |
| Li, XW | 1 |
| Cazzaniga, M | 1 |
| Bonanni, B | 1 |
| Rezaei, M | 1 |
| Keshtzar, E | 1 |
| Khodayar, MJ | 1 |
| Javadipour, M | 1 |
| Wang, AT | 1 |
| Meng, XT | 1 |
| Yang, ZR | 1 |
| Guan, HS | 1 |
| Wang, CY | 1 |
| Zhu, SL | 1 |
| Zhou, XM | 1 |
| Zhu, XP | 1 |
| Bai, JY | 1 |
| Xia, P | 1 |
| Galletti, F | 1 |
| Fazio, V | 1 |
| Gentile, M | 1 |
| Schillaci, G | 1 |
| Pucci, G | 1 |
| Battista, F | 1 |
| Mercurio, V | 2 |
| Bosso, G | 1 |
| Bonaduce, D | 1 |
| Brambilla, N | 1 |
| Vitalini, C | 1 |
| D'Amato, M | 1 |
| Giacovelli, G | 1 |
| Wu, L | 1 |
| Xia, M | 1 |
| Jiang, H | 1 |
| Hu, X | 1 |
| Yan, H | 2 |
| Shi, H | 1 |
| Chang, W | 2 |
| Wei, S | 1 |
| Du, H | 1 |
| Pérez-Rubio, KG | 1 |
| González-Ortiz, M | 1 |
| Martínez-Abundis, E | 1 |
| Robles-Cervantes, JA | 1 |
| Espinel-Bermúdez, MC | 1 |
| Ma, H | 1 |
| Ng, EH | 1 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Li, R | 1 |
| Wu, J | 1 |
| Hai, L | 1 |
| Wu, Y | 1 |
| Caliceti, C | 1 |
| Rizzo, P | 1 |
| Cicero, AF | 3 |
| Trimarco, V | 1 |
| Izzo, R | 1 |
| Stabile, E | 1 |
| Rozza, F | 1 |
| Santoro, M | 1 |
| Manzi, MV | 1 |
| Serino, F | 1 |
| Schiattarella, GG | 1 |
| Esposito, G | 1 |
| Trimarco, B | 1 |
| Rosticci, M | 1 |
| Parini, A | 1 |
| Morbini, M | 1 |
| Urso, R | 1 |
| Grandi, E | 1 |
| Borghi, C | 1 |
| Jiang, SJ | 1 |
| Li, JB | 1 |
| Wang, KF | 3 |
| Wu, U | 1 |
| Cha, Y | 1 |
| Huang, X | 1 |
| Chen, Z | 1 |
| Wang, F | 1 |
| Ding, H | 1 |
| Zhao, YB | 1 |
| Wang, DK | 1 |
| Fang, K | 1 |
| Zhang, DS | 1 |
| Bai, XH | 1 |
| Yao, YJ | 1 |
| Mu, DZ | 1 |
| Geng, FH | 1 |
| Li, GH | 1 |
| Zhang, P | 1 |
| Dong, MQ | 1 |
| Zhao, ZJ | 1 |
| Cao, Y | 1 |
| Pan, Q | 1 |
| Cai, W | 1 |
| Shen, F | 1 |
| Chen, GY | 1 |
| Xu, LM | 1 |
| Fan, JG | 1 |
| Yang, W | 1 |
| She, L | 1 |
| Yu, K | 1 |
| Yan, S | 1 |
| Tian, X | 1 |
| Ma, S | 1 |
| Zhu, X | 1 |
| Bian, H | 1 |
| Sun, J | 1 |
| Zhang, YJ | 1 |
| Chai, QY | 1 |
| Zhang, K | 1 |
| Ma, HL | 1 |
| Wu, XK | 1 |
| Liu, JP | 1 |
| Sun, H | 2 |
| Wang, N | 2 |
| Cang, Z | 2 |
| Zhu, C | 1 |
| Nie, X | 2 |
| Xia, F | 1 |
| Zhai, H | 1 |
| Zhou, H | 1 |
| Feng, L | 1 |
| Xu, F | 1 |
| Ma, Y | 2 |
| Liu, H | 1 |
| Xu, G | 1 |
| Shen, Y | 2 |
| Xu, Q | 1 |
| Gao, Z | 2 |
| Leng, S | 1 |
| Xie, M | 1 |
| Wang, K | 1 |
| Kong, WJ | 1 |
| Zhang, H | 2 |
| Song, DQ | 1 |
| Xue, R | 1 |
| Zhao, W | 1 |
| Wei, J | 1 |
| Wang, YM | 1 |
| Shan, N | 1 |
| Zhou, ZX | 1 |
| Yang, P | 1 |
| You, XF | 1 |
| Li, ZR | 1 |
| Si, SY | 1 |
| Zhao, LX | 1 |
| Pan, HN | 1 |
| Jiang, JD | 1 |
| Zhang, W | 1 |
| Xu, YC | 1 |
| Guo, FJ | 1 |
| Meng, Y | 1 |
| Li, ML | 1 |
| Ruvolo, A | 2 |
| Micillo, F | 1 |
| Saccà, L | 1 |
| Wen, Y | 1 |
| Sun, C | 1 |
| Kuang, HY | 1 |
| Liu, LZ | 1 |
| Cheung, SC | 1 |
| Lan, LL | 1 |
| Ho, SK | 1 |
| Xu, HX | 1 |
| Chan, JC | 1 |
| Tong, PC | 1 |
| Campbell, T | 1 |
| Perry, B | 1 |
| Beaurepaire, C | 1 |
| Qin, L | 1 |
| Wang, ZS | 2 |
| Wang, XX | 1 |
| Liu, YC | 1 |
| Chen, C | 1 |
| Huang, C | 1 |
| Chang, X | 1 |
| Fei, J | 1 |
| Jiang, M | 1 |
| Zhu, H | 3 |
| Lu, D | 1 |
| Ma, C | 1 |
| Qin, C | 2 |
| Han, F | 1 |
| Baillargeon, JP | 1 |
| Lou, T | 1 |
| Zhang, Z | 2 |
| Xi, Z | 1 |
| Liu, K | 1 |
| Huang, F | 1 |
| Dvorak, Z | 1 |
| Vrzal, R | 1 |
| Wei, SC | 1 |
| Chen, G | 3 |
| Ma, CM | 1 |
| Wang, P | 1 |
| Zhuang, Y | 1 |
| Lin, H | 2 |
| Liu, L | 1 |
| Meng, Q | 1 |
| Cui, T | 1 |
| Xing, LJ | 1 |
| Liu, T | 1 |
| Hua, YQ | 1 |
| Zheng, PY | 1 |
| Ji, G | 1 |
| Wei, W | 1 |
| Wang, A | 1 |
| Sui, M | 1 |
| Liang, K | 1 |
| Deng, H | 1 |
| Gomes, AP | 1 |
| Duarte, FV | 1 |
| Nunes, P | 1 |
| Hubbard, BP | 1 |
| Teodoro, JS | 1 |
| Varela, AT | 1 |
| Jones, JG | 1 |
| Sinclair, DA | 1 |
| Palmeira, CM | 1 |
| Rolo, AP | 1 |
| Wu, S | 1 |
| Carlomagno, G | 1 |
| Pirozzi, C | 1 |
| Tartagni, E | 1 |
| Rahigude, AB | 1 |
| Kaulaskar, SV | 1 |
| Bhutada, PS | 1 |
| Pang, X | 1 |
| Kang, C | 1 |
| Ning, G | 2 |
| Shen, N | 1 |
| Huan, Y | 1 |
| Shen, ZF | 1 |
| Bharti, SK | 1 |
| Krishnan, S | 1 |
| Kumar, A | 1 |
| Rajak, KK | 1 |
| Murari, K | 1 |
| Bharti, BK | 1 |
| Gupta, AK | 1 |
| Gu, JJ | 1 |
| Gao, FY | 1 |
| Zhao, TY | 1 |
| Lee, YS | 1 |
| Kim, WS | 1 |
| Kim, KH | 1 |
| Yoon, MJ | 1 |
| Cho, HJ | 1 |
| Ye, JM | 1 |
| Lee, CH | 1 |
| Oh, WK | 1 |
| Kim, CT | 1 |
| Hohnen-Behrens, C | 1 |
| Gosby, A | 1 |
| Kraegen, EW | 1 |
| James, DE | 1 |
| Kim, JB | 1 |
| Yin, J | 1 |
| Zou, D | 1 |
| Yang, J | 1 |
| Zhu, N | 1 |
| Huo, L | 1 |
| Wang, M | 1 |
| Hong, J | 1 |
| Wu, P | 1 |
| Ren, G | 1 |
| Gao, CR | 1 |
| Zhang, JQ | 1 |
| Huang, QL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Amla Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion.[NCT03633630] | Phase 2/Phase 3 | 28 participants (Actual) | Interventional | 2019-04-01 | Completed | ||
| Effect of Berberine on Hormonal and Metabolic Features in Obese Women With PCOS[NCT01138930] | 120 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | |||
| Randomized Trial to Evaluate the Effects of Two Different Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve in Hypercholesterolemic Patients at Moderate Cardiovascular Risk[NCT02969070] | 28 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| Effects of a New Combination of Nutraceutics (LopiGLIK®) on Cardiovascular Risk[NCT02898805] | 600 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial[NCT02806999] | Phase 4 | 200 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | ||
| The Study of Berberine Affecting Metabolism, Inflammation Status, Endothelial Function and Thrombotic Events in Patients With Coronary Artery Disease by Remodeling Gut Microbiota[NCT04434365] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2019-06-21 | Active, not recruiting | ||
| The Effect of Policosanol on Elderly Patients With Endothelial Dysfunction[NCT02543099] | Phase 3 | 100 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Effect of a Nutraceutical Combination on Endothelial Injury and C-reactive Protein in Patients With Low-grade Systemic Inflammation[NCT02422927] | Phase 4 | 100 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for berberine and Insulin Resistance
| Article | Year |
|---|---|
Berberine in Non-Alcoholic Fatty Liver Disease-A Review.
Topics: Berberine; Gluconeogenesis; Humans; Insulin Resistance; Lipogenesis; Liver; Non-alcoholic Fatty Live | 2022 |
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus.
Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re | 2022 |
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus.
Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re | 2022 |
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus.
Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re | 2022 |
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus.
Topics: Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin Re | 2022 |
A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention.
Topics: Animals; Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; | 2023 |
Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review.
Topics: Berberine; Blood Glucose; China; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Randomized C | 2019 |
The effect of Berberine on weight loss in order to prevent obesity: A systematic review.
Topics: Adipocytes; Berberine; Blood Glucose; Cholesterol; Gastrointestinal Microbiome; Gluconeogenesis; Hum | 2020 |
The effect and safety of Berberine on polycystic ovary syndrome: a systematic review.
Topics: Adult; Androstenedione; Berberine; Body Mass Index; Female; Follicle Stimulating Hormone; Humans; In | 2021 |
Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine.
Topics: Animals; Berberine; Drug Delivery Systems; Gastrointestinal Microbiome; Humans; Insulin Resistance; | 2021 |
Berberine in the Treatment of Diabetes Mellitus: A Review.
Topics: Animals; Berberine; Diabetes Mellitus; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Secreti | 2021 |
Effects of Berberine on the Gastrointestinal Microbiota.
Topics: Animals; Atherosclerosis; Berberine; China; Gastrointestinal Microbiome; Humans; Insulin Resistance | 2020 |
Effect and mechanism of berberine against polycystic ovary syndrome.
Topics: Animals; Berberine; Female; Humans; Insulin Resistance; Metabolic Syndrome; Polycystic Ovary Syndrom | 2021 |
Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease.
Topics: Berberine; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Liver; Non-alcoholic Fatty Liver D | 2021 |
A spotlight on underlying the mechanism of AMPK in diabetes complications.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Diabetes Complications; Diabetes Mellitus, Type 2 | 2021 |
Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Topics: Berberine; Clinical Decision-Making; Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin | 2021 |
Chinese Herbal Medicine for the Optimal Management of Polycystic Ovary Syndrome.
Topics: Androgens; Berberine; Drugs, Chinese Herbal; Female; Ginsenosides; Glucosides; Humans; Insulin Resis | 2017 |
Nutraceutical approaches to metabolic syndrome.
Topics: Berberine; Biological Products; Blood Glucose; Blood Pressure; Curcumin; Dietary Supplements; Female | 2017 |
[Berberine regulates type 2 diabetes mellitus related with insulin resistance].
Topics: Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Humans; Hypoglycemic Agents; Insulin Re | 2017 |
Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
Topics: Berberine; Blood Glucose; Breast Neoplasms; Female; Humans; Incidence; Insulin Resistance; Metabolic | 2018 |
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea.
Topics: Antioxidants; Berberine; Beverages; Clinical Trials as Topic; Expert Testimony; Humans; Hypoglycemic | 2014 |
Potential benefits of berberine in the management of perimenopausal syndrome.
Topics: Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; L | 2015 |
The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Clinical Trials as Topic; DNA Damage; Gene Expres | 2016 |
Antidiabetic properties of berberine: from cellular pharmacology to clinical effects.
Topics: Animals; Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; | 2012 |
12 trials available for berberine and Insulin Resistance
| Article | Year |
|---|---|
Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study.
Topics: Adult; Berberine; Body Composition; Endpoint Determination; Female; Hormones; Humans; Inflammation; | 2021 |
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection.
Topics: Adult; Berberine; Double-Blind Method; Female; HIV Infections; Humans; Insulin Resistance; Metabolic | 2023 |
Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial.
Topics: Adult; Aged; Berberine; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Fatty Alcohols; | 2019 |
Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion.
Topics: Adult; Area Under Curve; Berberine; Blood Glucose; Blood Pressure; Cholesterol, HDL; Double-Blind Me | 2013 |
Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Berberine; Biomarkers; Blood Glucose; China; Clinical Proto | 2013 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial.
Topics: Adult; Aged; Berberine; Chlorogenic Acid; Cross-Over Studies; Dietary Supplements; Double-Blind Meth | 2015 |
The effect of berberine on insulin resistance in women with polycystic ovary syndrome: detailed statistical analysis plan (SAP) for a multicenter randomized controlled trial.
Topics: Adolescent; Adult; Berberine; Clinical Protocols; Data Interpretation, Statistical; Drugs, Chinese H | 2016 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome.
Topics: Berberine; Cholesterol; Cholesterol, LDL; Female; Humans; Insulin Resistance; Metformin; Polycystic | 2012 |
Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome.
Topics: Anticholesteremic Agents; Berberine; Cardiotonic Agents; Dietary Supplements; Fatty Alcohols; Female | 2012 |
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.
Topics: Adult; Aged; Berberine; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidem | 2008 |
86 other studies available for berberine and Insulin Resistance
| Article | Year |
|---|---|
Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites.
Topics: Animals; Berberine; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Female; Gastrointestinal Micr | 2021 |
WJCPR11 reverses the TNF-α-induced inhibition of adipocyte differentiation and glucose uptake.
Topics: Adipocytes; Animals; Berberine; Cell Differentiation; Cells, Cultured; Glucose; Insulin Resistance; | 2021 |
Synergetic protective effect of berberine and ginsenoside Rb1 against tumor necrosis factor alpha-induced inflammation in adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Berberine; Cell Proliferation; Cell Survival; Drug | 2021 |
Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice.
Topics: Animals; Berberine; Diet, High-Fat; Gastrointestinal Microbiome; Insulin Resistance; Mice; Mice, Inb | 2023 |
Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Line; Diabetes Mellitus, Experimental; Epitheli | 2021 |
Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2α.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Berberine; Ceramides; Diabetes Mellitus, Type | 2022 |
Berberine Improves TNF-α-Induced Hepatic Insulin Resistance by Targeting MEKK1/MEK Pathway.
Topics: Berberine; Humans; Insulin; Insulin Resistance; Isoquinolines; MAP Kinase Signaling System; Mitogen- | 2022 |
Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice.
Topics: Animals; Berberine; Chromatography, Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2022 |
A Composition of Phytonutrients for Glycemic and Weight Management.
Topics: Acrolein; Animals; Berberine; Blood Glucose; Curcumin; Diabetes Mellitus; Disease Models, Animal; Fa | 2022 |
High fructose-induced skeletal muscle insulin resistance could be alleviated by berberine via AMPD1 and ADSL.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adenylosuccinate Synthase; AMP-Activated Protein Ki | 2023 |
Simulated weightlessness induces hippocampal insulin resistance and cognitive impairment.
Topics: Animals; Berberine; Cognitive Dysfunction; Hippocampus; Insulin; Insulin Resistance; Memory Disorder | 2023 |
Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Homeostasis | 2023 |
Berberine chloride ameliorated PI3K/Akt-p/SIRT-1/PTEN signaling pathway in insulin resistance syndrome induced in rats.
Topics: Animals; Berberine; Blood Glucose; Diet, High-Fat; Insulin; Insulin Resistance; Lipid Metabolism; Li | 2019 |
Berberine attenuates olanzapine induced-metabolic syndrome.
Topics: Animals; Berberine; Biomarkers; Insulin Resistance; Male; Metabolic Syndrome; Olanzapine; Prospectiv | 2019 |
Berberine improves insulin resistance in adipocyte models by regulating the methylation of hypoxia-inducible factor-3α.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Apoptosis Regulatory Proteins; Berberine; Diabetes, Gestat | 2019 |
Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways.
Topics: Animals; Berberine; DNA-Binding Proteins; Female; Insulin Resistance; Mitogen-Activated Protein Kina | 2020 |
ATP reduces mitochondrial MECR protein in liver of diet-induced obese mice in mechanism of insulin resistance.
Topics: 3T3-L1 Cells; Adenosine Triphosphate; Animals; Berberine; Diet, High-Fat; Disease Models, Animal; Do | 2020 |
Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Diabetes Mellitus, Experimental; | 2020 |
Berberine improves intralipid-induced insulin resistance in murine.
Topics: Animals; Berberine; Cell Line; Cyclophilins; Emulsions; Humans; Hyperinsulinism; Hypoglycemic Agents | 2021 |
The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome.
Topics: Adult; Anti-Inflammatory Agents; Anti-Mullerian Hormone; Berberine; Cells, Cultured; Female; Glycoli | 2020 |
Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance
Topics: Animals; Berberine; Cell Line; Dexamethasone; Diabetes Mellitus, Experimental; Drug Evaluation, Prec | 2020 |
Jateorhizine alleviates insulin resistance by promoting adipolysis and glucose uptake in adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Berberine; Cell Differentiation; Gene Expression | 2021 |
Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis.
Topics: Animals; Apoptosis; Berberine; Diet, High-Fat; Female; Gene Expression; Inflammation; Insulin Resist | 2021 |
Protective effects of berberine in a rat model of polycystic ovary syndrome mediated via the PI3K/AKT pathway.
Topics: Animals; Berberine; Female; Humans; Insulin Resistance; Phosphatidylinositol 3-Kinases; Polycystic O | 2021 |
[Effect of berberine on insulin resistance in diabetic rats].
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insul | 2020 |
Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway.
Topics: Amyloid beta-Peptides; Animals; Berberine; Cell Line, Tumor; Cognitive Dysfunction; Diabetes Mellitu | 2021 |
Berberine and Ginsenoside Rb1 Ameliorate Depression-Like Behavior in Diabetic Rats.
Topics: Animals; Berberine; Blood Glucose; Depression; Diabetes Mellitus, Experimental; Diet, High-Fat; Drug | 2021 |
Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action.
Topics: Animals; Apoptosis; Berberine; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diet, High-Fa | 2021 |
Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3.
Topics: Adipose Tissue; Animals; Berberine; Diet, High-Fat; Inflammation; Insulin Resistance; Mice; MicroRNA | 2022 |
Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.
Topics: Adipose Tissue, Brown; AMP-Activated Protein Kinases; Animals; Berberine; Blotting, Western; Body We | 2021 |
[Regulations of berberine on gene expression of BMP4 transcriptional pathways to improve visceral white adipose tissues insulin resistance in type 2 diabetic hamsters].
Topics: Activating Transcription Factor 2; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Berberine; | 2016 |
[Effects of berberine on mRNA expression levels of PPARγ and adipocytokines in insulin-resistant adipocytes].
Topics: 3T3-L1 Cells; Adipocytes; Adipokines; Animals; Berberine; Insulin Resistance; Mice; PPAR gamma; RNA, | 2016 |
Synthesis, Characterization, and Biological Evaluations of 1,3,5-Triazine Derivatives of Metformin Cyclization with Berberine and Magnolol in the Presence of Sodium Methylate.
Topics: Anti-Inflammatory Agents; Berberine; Biphenyl Compounds; Cyclization; Humans; Inflammation; Insulin | 2017 |
Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway.
Topics: Animals; Berberine; Blood Glucose; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Drugs, | 2018 |
Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Berberine; Cognition; Cognitive Dysfunction; Diet, Hi | 2018 |
Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes.
Topics: Animals; Berberine; Cattle; Cells, Cultured; Electron Transport; Fatty Acids, Nonesterified; Fatty L | 2018 |
SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification.
Topics: Animals; Arsenic; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Electron Transport Complex II | 2019 |
Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; | 2019 |
[Differentiated hypoglycemic effects of baicalin, berberine and puerarin on insulin-resistance HepG2 cells].
Topics: Berberine; Flavonoids; Glucose; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Resistan | 2018 |
Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Topics: Acetylation; Acyl-CoA Dehydrogenase, Long-Chain; Animals; Berberine; Carnitine; Diet, High-Fat; Drug | 2019 |
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans.
Topics: Adipocytes; Adipose Tissue, Brown; Adult; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agent | 2019 |
Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Berberine; Blott | 2013 |
Synthesis and in vitro evaluation of 12-(substituted aminomethyl) berberrubine derivatives as anti-diabetics.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2014 |
Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.
Topics: Active Transport, Cell Nucleus; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AM | 2015 |
Berberine treatment attenuates the palmitate-mediated inhibition of glucose uptake and consumption through increased 1,2,3-triacyl-sn-glycerol synthesis and accumulation in H9c2 cardiomyocytes.
Topics: Animals; Berberine; Biological Transport; Cell Line; Diacylglycerol O-Acyltransferase; Diglycerides; | 2016 |
Protective effects of berberine on high fat-induced kidney damage by increasing serum adiponectin and promoting insulin sensitivity.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Berberine; Blood Glucose; C-Reactive Protein; C | 2015 |
Berberine relieves insulin resistance via the cholinergic anti-inflammatory pathway in HepG2 cells.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Berberine; Glucose; Hep G2 Cells; Humans; Hypoglycemic Agen | 2016 |
[Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance].
Topics: Animals; Berberine; Diet, High-Fat; I-kappa B Kinase; Insulin; Insulin Receptor Substrate Proteins; | 2015 |
Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats.
Topics: Acetylcholine; Animals; Berberine; Blood Glucose; Cell Line; Endothelium, Vascular; Humans; Insulin; | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal | 2016 |
Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model.
Topics: Animals; Berberine; Body Weight; Coptis; Diet, High-Fat; Hyperlipidemias; Hypolipidemic Agents; Insu | 2016 |
Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats.
Topics: Animals; Berberine; Brain; Diet, High-Fat; Energy Metabolism; Gastrointestinal Microbiome; Glucagon- | 2016 |
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Carbohydrate Metabolism; Diet, High-Fat | 2017 |
Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement.
Topics: Animals; Autophagy; Berberine; Cytokines; Gene Expression Regulation; Inflammasomes; Insulin Resista | 2017 |
Effect of berberine on expression of hepatocyte nuclear factor-4alpha in rats with fructose-induced insulin resistance.
Topics: Animals; Berberine; Blood Glucose; Fructose; Hepatocyte Nuclear Factor 4; Immunohistochemistry; Insu | 2008 |
Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression.
Topics: Animals; Berberine; Cell Line, Tumor; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; | 2009 |
Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus.
Topics: Acrolein; Animals; Berberine; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Glucose Tra | 2008 |
Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
Topics: Anilides; Berberine; Blotting, Western; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; | 2009 |
[Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells].
Topics: Animals; Berberine; Cells, Cultured; Female; Insulin Resistance; Isoflavones; Ovary; Swine; Theca Ce | 2009 |
Berberine modulates insulin signaling transduction in insulin-resistant cells.
Topics: Actins; Animals; Berberine; Glucose; Glucose Transporter Type 4; Insulin; Insulin Resistance; Mice; | 2010 |
Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.
Topics: Adiponectin; Animals; Berberine; Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, | 2011 |
Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Berberine; Cell Survival; Endoplasmic Reticulum; Glucose | 2010 |
[Controlling effect of berberine on in vitro synthesis and metabolism of steroid hormones in insulin resistant ovary].
Topics: 17-alpha-Hydroxyprogesterone; Androstenedione; Animals; Berberine; Female; In Vitro Techniques; Insu | 2010 |
Berberine inhibits PTP1B activity and mimics insulin action.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Diet; Female; Hyperglycemia; Hypoglycemic Agents; Insu | 2010 |
Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.
Topics: Amino Acid Sequence; Animals; Base Sequence; Berberine; Carrier Proteins; Diet; Dietary Fats; DNA Me | 2010 |
Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs.
Topics: Animals; Berberine; Cricetinae; Diabetes Mellitus, Type 2; Female; Gene Expression Profiling; Gene E | 2010 |
Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro.
Topics: Berberine; Cells, Cultured; Dexamethasone; Drug Interactions; Female; Glucocorticoids; Glucose; Huma | 2011 |
Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes.
Topics: Berberine; Cell Line; Hepatocytes; Humans; Inflammation; Insulin Receptor Substrate Proteins; Insuli | 2011 |
Berberine reduces insulin resistance: the roles for glucocorticoid receptor and aryl hydrocarbon receptor.
Topics: Animals; Berberine; Down-Regulation; Drug Interactions; Female; Gene Expression Regulation; HeLa Cel | 2011 |
[8-hydroxy-dihydroberberine ameliorated insulin resistance induced by high FFA and high glucose in 3T3-L1 adipocytes].
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Cell Differentiation; Glucose; Hypoglycemic Agents; In | 2009 |
Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver x receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters.
Topics: Adipose Tissue; Animals; Base Sequence; Berberine; Cricetinae; Diabetes Mellitus, Type 2; DNA Primer | 2011 |
Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adiponectin; AMP-Activated Protein Kinase Kinases; Animals; Berberine; Enzyme Activati | 2011 |
Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.
Topics: Animals; Berberine; Fatty Liver; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin Re | 2011 |
Adiponectin self-regulates its expression and multimerization in adipose tissue: an autocrine/paracrine mechanism?
Topics: Adiponectin; Adipose Tissue; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Autocrine Co | 2012 |
Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cell Line; Diet, High-Fat; Glucose; Hormones; Hyp | 2012 |
[Effects of berberine on the pancreatic beta cell apoptosis in rats with insulin resistance].
Topics: Animals; Apoptosis; Berberine; Blood Glucose; Caspase 12; Cell Line; Insulin Resistance; Insulin-Sec | 2011 |
Possible therapeutic potential of berberine in diabetic osteopathy.
Topics: Berberine; Calcitonin; Diabetes Complications; Glucagon-Like Peptides; Glycation End Products, Advan | 2012 |
Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats.
Topics: Adiposity; Animals; Berberine; Diet, High-Fat; Fatty Acids, Volatile; Feces; Feeding Behavior; Gastr | 2012 |
Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Blood Glucose; Cell Line; Diet, High-Fat; Enzyme | 2012 |
Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking.
Topics: Alkaloids; Animals; Berberine; Blood Glucose; Castanospermum; Diabetes Mellitus, Experimental; Diabe | 2012 |
A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats.
Topics: Animals; Berberine; Cells, Cultured; Diet, High-Fat; Fatty Acids, Nonesterified; Glucagon; Glucagon- | 2012 |
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Cell Li | 2006 |
Berberine improves glucose metabolism through induction of glycolysis.
Topics: 3T3-L1 Cells; Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes; AMP-Activated Protein Kin | 2008 |
[Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes].
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Blotting, Western; Fatty Acids, Nonesterified; Glucose | 2007 |
Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta.
Topics: 3T3-L1 Cells; Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Adipocytes; Anim | 2008 |
[Experimental study on berberin raised insulin sensitivity in insulin resistance rat models].
Topics: Animals; Berberine; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Metformin | 1997 |